Cross-agency comparison: 🇪🇺 EMA leads with 71 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

The EMA’s much higher output suggests a more active and possibly more dynamic regulatory environment than the FDA, MHRA, or Health Canada over this period, which may indicate greater movement in guidance, expectations, or procedural updates that sponsors should monitor closely. For companies planning multi-market submissions, this could suggest prioritizing Europe for surveillance and dossier adaptation, while still recognizing that the UK and Canada are also relatively active and may require dedicated local regulatory attention rather than simple “follow-the-FDA” alignment. Strategically, this argues for a filing plan with flexible core content, region-specific gap assessments, and enough regulatory bandwidth to absorb faster-moving changes in the most active markets.